Trial · NCT00856492
Adverse events468
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 468
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 73 | 96 | |
| other | Anemia | Blood and lymphatic system disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 43 | 60 | |
| other | Anemia | Blood and lymphatic system disorders | Arm III (AC+PEG-G - Nab-Paclitaxel) | 48 | 51 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 7 | 96 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 4 | 60 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm III (AC+PEG-G - Nab-Paclitaxel) | 3 | 51 | |
| other | Sinus tachycardia | Cardiac disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 5 | 96 | |
| other | Sinus tachycardia | Cardiac disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 1 | 60 | |
| other | Sinus tachycardia | Cardiac disorders | Arm III (AC+PEG-G - Nab-Paclitaxel) | 2 | 51 | |
| other | Ear pain | Ear and labyrinth disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 4 | 96 | |
| other | Ear pain | Ear and labyrinth disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 1 | 60 | |
| other | Ear pain | Ear and labyrinth disorders | Arm III (AC+PEG-G - Nab-Paclitaxel) | 4 | 51 | |
| other | Blurred vision | Eye disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 6 | 96 | |
| other | Blurred vision | Eye disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 8 | 60 | |
| other | Blurred vision | Eye disorders | Arm III (AC+PEG-G - Nab-Paclitaxel) | 5 | 51 | |
| other | Conjunctivitis | Eye disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 2 | 96 | |
| other | Conjunctivitis | Eye disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 1 | 60 | |
| other | Conjunctivitis | Eye disorders | Arm III (AC+PEG-G - Nab-Paclitaxel) | 4 | 51 | |
| other | Dry eye | Eye disorders | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 3 | 96 | |
| other | Dry eye | Eye disorders | Arm II (Nab-Paclitaxel - AC+PEG-G) | 2 | 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00856492/events